Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Cash from Financing Activities: 2020-2025

Historic Cash from Financing Activities for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Sep 2025 value amounting to $1.5 million.

  • Arcutis Biotherapeutics' Cash from Financing Activities rose 274.62% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$94.2 million, marking a year-over-year decrease of 135.82%. This contributed to the annual value of $66.2 million for FY2024, which is 34.66% down from last year.
  • Latest data reveals that Arcutis Biotherapeutics reported Cash from Financing Activities of $1.5 million as of Q3 2025, which was up 6.96% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Cash from Financing Activities registered a high of $285.0 million during Q3 2022, and its lowest value of -$97.4 million during Q4 2024.
  • Moreover, its 3-year median value for Cash from Financing Activities was $1.1 million (2023), whereas its average is $15.5 million.
  • As far as peak fluctuations go, Arcutis Biotherapeutics' Cash from Financing Activities soared by 452,263.49% in 2022, and later slumped by 198.11% in 2024.
  • Quarterly analysis of 5 years shows Arcutis Biotherapeutics' Cash from Financing Activities stood at $72.9 million in 2021, then plummeted by 98.68% to $962,000 in 2022, then skyrocketed by 10,221.10% to $99.3 million in 2023, then slumped by 198.11% to -$97.4 million in 2024, then spiked by 274.62% to $1.5 million in 2025.
  • Its Cash from Financing Activities stands at $1.5 million for Q3 2025, versus $1.4 million for Q2 2025 and $395,000 for Q1 2025.